PROF vs. BBNX, BFLY, BVS, EMBC, AXGN, SIBN, AVNS, IRMD, TMCI, and KIDS
Should you be buying Profound Medical stock or one of its competitors? The main competitors of Profound Medical include Beta Bionics (BBNX), Butterfly Network (BFLY), Bioventus (BVS), Embecta (EMBC), AxoGen (AXGN), SI-BONE (SIBN), Avanos Medical (AVNS), Iradimed (IRMD), Treace Medical Concepts (TMCI), and OrthoPediatrics (KIDS). These companies are all part of the "medical equipment" industry.
Profound Medical vs.
Beta Bionics (NASDAQ:BBNX) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment.
Beta Bionics has a net margin of 0.00% compared to Profound Medical's net margin of -349.41%. Beta Bionics' return on equity of 0.00% beat Profound Medical's return on equity.
Beta Bionics presently has a consensus target price of $24.83, suggesting a potential upside of 18.37%. Profound Medical has a consensus target price of $14.25, suggesting a potential upside of 103.86%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than Beta Bionics.
In the previous week, Beta Bionics had 13 more articles in the media than Profound Medical. MarketBeat recorded 17 mentions for Beta Bionics and 4 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.75 beat Beta Bionics' score of 0.53 indicating that Profound Medical is being referred to more favorably in the news media.
Beta Bionics has higher revenue and earnings than Profound Medical.
Profound Medical received 34 more outperform votes than Beta Bionics when rated by MarketBeat users. Likewise, 72.73% of users gave Profound Medical an outperform vote while only 66.67% of users gave Beta Bionics an outperform vote.
47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Profound Medical beats Beta Bionics on 8 of the 14 factors compared between the two stocks.
Get Profound Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Profound Medical Competitors List
Related Companies and Tools
This page (NASDAQ:PROF) was last updated on 3/4/2025 by MarketBeat.com Staff
Free PROF Stock Alerts